Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV Dynamics to resubmit Omnicarbon PMA to FDA within a few months.

This article was originally published in The Gray Sheet

Executive Summary

CV DYNAMICS OMNICARBON CARDIAC VALVE PMA RESUBMISSION will come within the next few months, the company estimates. CV Dynamics plans to submit a revised version of a premarket approval application for the heart valve that was rejected by the agency in 1989. The company plans to supplement the filing with information including updated clinical data and comprehensive fatigue data on the Omnicarbon's pyrolite housing.

You may also be interested in...

MedicalCV's Omnicarbon Heart Valve To Launch In August After 15-Year Wait

MedicalCV aims to capture 1-2% of the roughly $360 mil. worldwide mechanical heart valve market over the next year after gaining FDA approval of its Omnicarbon pyrolite ceramic-based heart valve on July 26.

Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts